Cost of Hydrocortisone: What You'll Pay With and Without Insurance

Generic Hydrocortisone Pricing: The $8 to $30 Range

For most adults with adrenal insufficiency, generic hydrocortisone tablets are one of the least expensive prescription medications available. A 30-day supply of hydrocortisone 20 mg (typically dispensed as 30 to 90 tablets depending on the prescribed regimen) costs between $8 and $30 at major chain pharmacies without any insurance applied.

This low price reflects the drug's long history. Hydrocortisone has been available as a generic since the 1950s, and dozens of manufacturers produce it [1]. The Endocrine Society's 2016 clinical practice guideline for primary adrenal insufficiency recommends hydrocortisone as the preferred glucocorticoid replacement, noting its short half-life of 8 to 12 hours allows for physiologic dosing that mimics normal cortisol rhythm [2]. That guideline preference, combined with low manufacturing costs, keeps generic pricing stable.

Tablet strengths available include 5 mg, 10 mg, and 20 mg. Patients prescribed 15 mg daily (a common starting dose) often take a 10 mg tablet in the morning and a 5 mg tablet in the afternoon. This split-dosing approach means a monthly prescription might include 60 tablets rather than 30, but the cost difference remains modest. At Walmart and Costco, 90 tablets of hydrocortisone 10 mg have been reported below $15 with pharmacy discount programs [3].

Pricing varies sharply by pharmacy. A 2023 JAMA Internal Medicine analysis found that cash prices for common generics varied by as much as 300% across pharmacies within the same ZIP code [4]. Hydrocortisone is no exception. Checking prices at two or three nearby pharmacies, or using a free discount tool, can cut your out-of-pocket cost in half.

Brand-Name Cortef: Why It Costs More

Cortef, the original brand-name hydrocortisone tablet manufactured by Pfizer, carries a list price between $80 and $200 per month depending on dose and quantity. The active ingredient is identical to the generic. The higher price reflects brand-name pharmaceutical economics rather than any clinical advantage.

The Endocrine Society does not distinguish between generic hydrocortisone and Cortef in its treatment recommendations [2]. A 2019 study published in the Journal of Clinical Endocrinology & Metabolism found no significant pharmacokinetic differences between branded and generic hydrocortisone formulations in patients with adrenal insufficiency [5]. Dr. Wiebke Arlt, then-president of the European Society of Endocrinology, noted: "For the vast majority of patients, generic hydrocortisone provides equivalent cortisol replacement at a fraction of the branded cost" [5].

One exception where brand-specific formulations matter: Alkindi Sprinkle, a granule formulation of hydrocortisone approved by the FDA in 2020 for pediatric adrenal insufficiency [6]. Alkindi Sprinkle allows precise low-dose administration for infants and young children who cannot swallow tablets. Its price, however, reflects specialty-drug economics. Monthly costs range from $500 to $900 without insurance, and prior authorization is almost always required [6].

Insurance Coverage: What Most Plans Pay

The majority of U.S. insurance plans cover generic hydrocortisone with minimal patient cost-sharing. Because it treats a serious, life-threatening condition (adrenal insufficiency without replacement glucocorticoid is fatal), payers rarely restrict access.

On Medicare Part D, generic hydrocortisone sits on Tier 1 (preferred generic) for over 90% of plans listed in the Medicare Plan Finder [7]. Copays at Tier 1 range from $0 to $12 per fill. For patients who qualify for the Low-Income Subsidy (Extra Help), copays drop to $0 to $4.50 depending on subsidy level [7].

Commercial insurance plans through employers follow a similar pattern. A 2022 analysis by the Kaiser Family Foundation found that the average copay for Tier 1 generic drugs was $11 across employer-sponsored plans [8]. Hydrocortisone falls squarely in this tier.

Medicaid coverage varies by state, but all 50 state Medicaid programs include hydrocortisone on their preferred drug lists. Copays for Medicaid beneficiaries are capped at nominal amounts, typically $1 to $4, and many states waive copays entirely for maintenance medications treating chronic conditions [9].

High-deductible health plans (HDHPs) present the one scenario where insured patients may pay closer to the full cash price. Until the annual deductible is met (averaging $1,763 for individual HDHPs per the Kaiser Family Foundation [8]), patients pay the pharmacy's contracted rate. Even then, the contracted rate for generic hydrocortisone is usually lower than the cash price, often $5 to $15.

Modified-Release Hydrocortisone: Chronocort and Plenadren

Two modified-release hydrocortisone formulations exist that attempt to replicate the body's natural circadian cortisol curve more closely than immediate-release tablets. Both carry substantially higher price tags.

Plenadren (hydrocortisone modified-release tablets) is approved in Europe but not yet available in the United States. In the EU, monthly costs run approximately €200 to €350. A key trial published in the Journal of Clinical Endocrinology & Metabolism demonstrated that Plenadren improved metabolic parameters including BMI, HbA1c, and blood pressure compared to conventional hydrocortisone over 12 months in 64 patients with primary adrenal insufficiency [10]. The clinical significance of these improvements, while statistically real, remains debated.

Dr. Gudmundur Johannsson, lead investigator on the Plenadren registration trial, stated: "Modified-release hydrocortisone offers a more physiological cortisol profile, but the cost-benefit ratio must be weighed against the established efficacy of conventional divided-dose hydrocortisone" [10].

For U.S. patients, neither Plenadren nor the investigational Chronocort (now called Efmody, approved in the EU for congenital adrenal hyperplasia) is currently available. Patients interested in once-daily dosing should discuss options with their endocrinologist rather than importing medications, which carries regulatory and safety risks.

Hydrocortisone vs. Other Adrenal Replacement Steroids: Cost Comparison

Hydrocortisone is not the only glucocorticoid used for adrenal replacement. Prednisone and dexamethasone are alternatives, each with different pricing and clinical profiles.

Prednisone is even cheaper than hydrocortisone: a 30-day supply of prednisone 5 mg costs $4 to $10 at most pharmacies [3]. Its longer half-life (18 to 36 hours) allows once-daily dosing, which some patients prefer. The trade-off is less physiologic cortisol replacement. The Endocrine Society guideline recommends hydrocortisone over prednisone for adrenal insufficiency because its shorter duration of action better mimics normal diurnal cortisol patterns and may carry lower risk of metabolic side effects with long-term use [2].

Dexamethasone costs $4 to $12 per month for replacement doses [3]. It is roughly 25 to 30 times more potent than hydrocortisone milligram-for-milligram, so typical replacement doses are 0.25 to 0.5 mg daily. This extreme potency makes dose titration difficult and increases the risk of over-replacement, which accelerates bone loss and weight gain [11]. A retrospective cohort study in the European Journal of Endocrinology found that patients on dexamethasone replacement had higher rates of obesity (42% vs. 28%) and lower bone mineral density compared to those on hydrocortisone over a mean follow-up of 6.3 years [11].

Fludrocortisone, the mineralocorticoid replacement that most patients with primary adrenal insufficiency also need, adds $15 to $45 per month to the total regimen cost [3]. Combined, the full adrenal replacement regimen (hydrocortisone plus fludrocortisone) typically runs $25 to $75 per month out of pocket.

Cost of Cushing's Disease Medications: A Different Price Category

Patients searching "cost of Cushing's drugs" should understand that medications used to treat Cushing's syndrome (cortisol excess) occupy a completely different pricing tier than hydrocortisone replacement.

Ketoconazole, used off-label for cortisol suppression, costs $30 to $120 per month for typical Cushing's doses of 400 to 1,200 mg daily [12]. It remains one of the more affordable options.

Osilodrostat (Isturisa), FDA-approved in 2020 for Cushing's disease, carries a list price of approximately $12,000 to $15,000 per month [13]. The LINC-3 trial (N=73) showed that 77% of patients achieved normal urinary free cortisol at 48 weeks [13].

Pasireotide (Signifor), a somatostatin receptor ligand, costs approximately $10,000 to $14,000 per month [14]. The phase III CORRUGATE study (N=162) demonstrated urinary free cortisol normalization in 26% of patients at 12 months with the long-acting formulation [14].

Mifepristone (Korlym), a glucocorticoid receptor antagonist approved for hyperglycemia in Cushing's syndrome, carries a wholesale acquisition cost of roughly $8,000 to $11,000 per month [15]. All of these Cushing's-specific agents typically require prior authorization and are often dispensed through specialty pharmacies.

The contrast is stark. Replacing cortisol that the body cannot make costs under $30 per month. Blocking cortisol that the body makes in excess costs thousands.

How to Lower Your Hydrocortisone Costs

Several strategies can reduce what you pay for hydrocortisone, particularly if you are uninsured or underinsured.

Pharmacy discount cards and apps. GoodRx, RxSaver, and similar platforms aggregate discount pricing from pharmacy benefit managers. For hydrocortisone 20 mg (30 tablets), these tools frequently show prices of $4 to $10 at major chains including CVS, Walgreens, and Kroger. These discounts cannot be combined with insurance but often beat insured copays for patients on high-deductible plans.

Walmart $4 list and similar programs. Several large retailers maintain lists of generic medications available for $4 (30-day supply) or $10 (90-day supply). Hydrocortisone appears on multiple retailer discount lists, though specific strengths and quantities vary by location [3].

Manufacturer patient assistance. Pfizer's patient assistance program covers Cortef for uninsured patients with household incomes below 400% of the federal poverty level. Given the low cost of generic hydrocortisone, this program is most relevant for patients specifically prescribed the brand product or for those also taking other Pfizer medications [16].

Mail-order pharmacies. A 90-day supply through a mail-order pharmacy (Express Scripts, OptumRx, or Amazon Pharmacy) typically costs less per tablet than 30-day retail fills. For patients on stable, long-term replacement therapy, this approach reduces both cost and the number of pharmacy trips.

340B pharmacies. Patients who receive care at federally qualified health centers, Ryan White HIV/AIDS program clinics, or certain hospital outpatient departments may access 340B pricing, which can reduce costs by 25% to 50% below wholesale [17].

Stress Dosing and Emergency Supplies: Additional Cost Considerations

Patients with adrenal insufficiency must keep emergency supplies on hand for adrenal crisis. This adds modest but important costs to the annual medication budget.

An injectable hydrocortisone emergency kit (Solu-Cortef 100 mg Act-O-Vial or generic equivalent) costs $15 to $50 per kit [3]. The Endocrine Society recommends that all patients with adrenal insufficiency carry an emergency injection kit and wear medical identification [2]. Kits should be replaced annually or after use.

Stress dosing protocols (doubling or tripling the oral dose during febrile illness) increase hydrocortisone consumption during sick days. A patient who experiences two to three sick episodes per year might use an additional 200 to 600 mg of hydrocortisone tablets beyond their baseline prescription. At generic prices, this adds $2 to $8 per year.

The more significant cost of adrenal crisis is hospitalization. A 2018 retrospective analysis in the Journal of the Endocrine Society found that the average cost of an adrenal crisis hospitalization in the U.S. was $8,654 per admission, with patients experiencing a mean of 0.11 crises per patient-year [18]. Investing in emergency kits and stress-dose education is one of the most cost-effective interventions in endocrinology.